New ALS drug
(`Motor Neuron Disease` or `MND` also known as `Lou Gehrig's disease`)
You can edit text on your website by double clicking on a text box on your website. Alternatively, when you select a 
A previously unknown problem protein has been discovered
A specifically designed new ALS drug, RCH4, successfully suppresses it
 ​RCH4 is available free of charge on compassionate basis depending on availability and location

For many years we have tendered our scientific papers to journals and submitted papers for oral presentation at various MND/ALS conferences. We had developed the only drug which substantially slowed the ALSFRS-R progression of ALS/MND for patients (by an average of 63%) over decades of patient-treatment years. No presenter at any conference had, or still has, ever achieved this as at 2018.
Our work was always been declined notwithstanding that fact. 
Example of a refusal below:
As in the case of the ALS Association, the Motor Neuron Disease Asssociation Chief Scientist was numerous times supplied with extensive clinical data but RCH4 was ignored.
Example: The Motor Neuron Disease Association: This is a screen shot (above) of an email sent to Dr. Belinda Cupid, Head of Research, MND Association in response to her note of rejection of papers submitted for an MND / ALS symposium. Compelling independent clinical data of the first drug ever to substantially slow the ALSFRS-R progression rate was provided in a table of itemised headings. 
We have no record of any reply from Dr. Cupid.

Note: RCH4 was available some years before Edaravone (Radicava).